poisar

Stocks · News reference

Scribe Therapeutics to Present Updated Data at AHA Scientific Sessions 2026

Fiscal.ai

Scribe Therapeutics announced it will present new preclinical data for its lead epigenetic silencing therapy, STX-1150, and its gene editing program, STX-1200, at the American Heart Association's Scientific Sessions.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolRick Munarriz

    Cathie Wood Bought Just 3 Stocks On Monday; Here They Are

    Cathie Wood's Ark Invest made selective purchases on Monday, adding to positions in Nvidia, SoFi Technologies, and Scribe Therapeutics despite a generally bullish market day. Nvidia faced headwinds from a spy scandal investigation involving CEO Jensen Huang but remains attractively valued. SoFi showed strong fundamentals with 35% member growth and 44% revenue increase, though it's down 41% over the past year. Scribe Therapeutics, a gene-editing biotech, has sufficient cash runway through early 2029.